Genfit: Positive liver disease drug results boost shares

Genfit SA

10/02/2021 09:07

** Shares in Genfit  GNFT.PA  rise 23%, having jumped as
much as 45%, after the drug developer announced positive results
of the phase 2 clinical trial evaluating its treatment
elafibranor in patients with primary biliary bholangitis (PBC)
 urn:newsml:reuters.com:*:nGNXjCfVB
    ** PBC is severe cholestatic liver disease that impacts and
gradually destroys bile ducts, leading to inflammation and
scarring of liver
    ** There is no existing cure for PBC and if left untreated,
can lead to cirrhosis, liver failure and may ultimately require
liver transplantation
    ** Stock is currently trading at mid-Sept levels, still down
about 75% from its highest 2020 levels from which it slumped on
May 12 after negative phase 3 elafibranor study in non-alcoholic
fatty liver disease (NASH)  urn:newsml:reuters.com:*:nL8N2CU347
    ** Today's gains added about EUR 34.4 mln to Genfit's market
cap
    ** Genfit is sitting on top of France's large- and mid-cap
index SBF 120  .SBF120 

 ((anait.miridzhanian@thomsonreuters.com))